This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cannabis ETF (CNBS) Hits New 52-Week High
by Zacks Equity Research
CNBS Cannabis ETF climbs to a 52-week high, fueled by rescheduling optimism and potential further gains.
6 Top-Performing ETF Areas of Last Week
by Sanghamitra Saha
Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.
5 Best-Performing Leveraged ETFs of Last Week
by Sanghamitra Saha
Cannabis, space, nat gas & auto led last week's leveraged ETF winners. MSOX, RKLX, KOLD, VOYX and CVNX posted outsized gains despite tech weakness.
Cannabis ETFs Soar Double-Digits on Friday: Here's Why
by Sanghamitra Saha
Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.
The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO
by Zacks Equity Research
Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.
From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects
by Aparajita Dutta
Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism.
Top-Performing ETF Areas of August That Are Up At Least 20%
by Sanghamitra Saha
ETFs tied to Cannabis, Asia, China, materials and bitcoin miners led August's gains in Wall Street. ETFs like WEED, KSTR, CNXT, GBUG and WGMI won in August.
Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification
by Sweta Killa
Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.
Sector ETFs to Win If Kamala Harris Wins Presidential Election
by Sanghamitra Saha
According to a recent survey, Kamala Harris is currently leading Donald Trump by some points. You should take notice of these sector ETFs.
Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week. The Fed's plan to slower the balance sheet tightening process and the release of downbeat jobs data dragged down bond yields.
Is Rescheduling a Certainty for Cannabis? ETFs That Surge
by Sanghamitra Saha
In a White House meeting, Vice President Kamala Harris this week urged the DEA to expedite the rescheduling of marijuana. President Biden also lately talked about ongoing efforts to review the federal classification of marijuana, hinting at his commitment to potential reforms
Cannabis ETFs Jump on Imminent Rescheduling News
by Sweta Killa
Cannabis stocks & ETFs jumped on Mar 15 after a prominent hedge fund manager suggested that regulators will soon reclassify marijuana as a less dangerous drug.
Cannabis Stocks & ETFs: Can the Recent Surge Continue?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Behind the Recent Surge in Marijuana ETFs
by Sanghamitra Saha
In a significant development, the Department of Health and Human Services (HHS) has recently initiated a review of marijuana's classification under the Controlled Substances Act.
Cannabis ETFs Soar on Hopes of Federal Legalization
by Sweta Killa
Marijuana stocks have been surging following a proposal by the Drug Enforcement Agency (???DEA???) to reclassify cannabis as a substance with reduced risk, fueling anticipation of federal legalization.
SAFE Banking Act Resurgence Boosts Pot ETFs: A New Era Ahead?
by Sanghamitra Saha
A fresh wave of investment opportunities emerges as the SAFE Banking Act is reintroduced to Congress, promising brighter prospects for marijuana stocks and ETFs.
Cannabis ETFs Trending Up to Start Q4
by Sweta Killa
Cannabis stocks and ETFs gained momentum to start the fourth quarter thanks to President Joe's announcement of a historic marijuana reform.
Cannabis ETFs Set to Soar on Passage of Legalization Bill
by Sweta Killa
Cannabis stocks are poised to surge further especially following the legislation passed by the House to legalize marijuana nationwide.
3 Winning ETF Areas of Last Week (Revised)
by Sanghamitra Saha
Along with rising rate worries, growing tensions between Russia and Ukraine weighed on the global markets last week.
3 Winning ETF Areas of Last Week
by Sanghamitra Saha
Along with rising rate worries, growing tensions between Russia and Ukraine weighed on the global markets last week.
After a Downbeat 2021, Will Marijuana ETFs Rebound in 2022?
by Sanghamitra Saha
Cannabis stocks and ETFs were massively downbeat in 2021. However, strong sales backdrop, growing medical usage and still-alive chances of a federal approval may cause a bounce back in pot ETFs in 2022.
Should You Buy Beaten Down Cannabis Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Cannabis ETFs Soar on Republican-Led Legalization Bill
by Sweta Killa
Cannabis ETFs have gained momentum lately following the reports of a Republican-led bill, which is seeking to legalize marijuana at the federal level in the United States.
Marijuana Secures Top-Performing ETF Spot Last Week
by Sanghamitra Saha
Wall Street was downbeat last week as a strong rally in the main indexes paused due to a high inflation.
5 ETF Teardowns: What's Under the Hood?
by Kevin Cook
Make screening for stocks more interesting with this investigative approach to ETFs.